Tevogen Bio Holdings INC 8-K filings

Tevogen Bio Holdings Inc. has officially changed its corporate name to Tevogen Inc., effective July 30, 2026, with no impact on security holders or trading symbols.

Tevogen Bio Holdings Inc. has been notified by Nasdaq that it fails to meet minimum market value requirements for continued listing.

Tevogen Bio Holdings Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-50 reverse stock split.

Tevogen Bio Holdings Inc. announced a 1-for-50 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective March 6, 2026.

Tevogen Bio Holdings Inc. stockholders approved a significant increase in shares for its incentive plan and authorized a reverse stock split to be implemented at the Board's discretion.

Tevogen Bio Holdings Inc. announced its Board of Directors intends to evaluate a potential one-time special cash dividend to shareholders, contingent on future financial milestones.

Tevogen Bio Holdings Inc. received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing.

Tevogen Bio Holdings Inc. announced a substantial increase in its outstanding common stock to 193,693,433 shares following restricted stock grants, including 8 million shares to CEO Dr. Ryan Saadi with a seven-year vesting commencement.

Tevogen Bio Holdings Inc. has entered into a sales agreement with A.G.P./Alliance Global Partners to sell up to $50 million of its common stock through an at-the-market equity offering.

Tevogen Bio Holdings Inc. announced that its CEO, Ryan Saadi, made a $500,000 cash contribution to fund the build-out and first-year operating costs of the company's new corporate headquarters in Warren, New Jersey.

Tevogen Bio Holdings Inc. announced the successful election of two Class I directors and the ratification of KPMG LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Tevogen Bio Holdings Inc. announced a significant amendment to its headquarters lease, doubling its office space and extending the term through February 2033, facilitating the consolidation of its research and development activities.

Tevogen Bio Holdings Inc. has amended its bylaws to modify the procedure for handling director resignations in uncontested elections where a director fails to receive a majority of votes.

Tevogen Bio finalizes an agreement with CD 8 Technology Services LLC to develop a turn-key facility for in-house cell therapy production.

Tevogen Bio announces a grant agreement with KRHP LLC for up to $10 million to support the development of T cell therapeutics and expansion of its artificial intelligence initiatives.

Tevogen Bio Holdings Inc. has entered into an agreement to sell $6 million of Series C Preferred Stock to an existing investor, with the closing split into two tranches.

Tevogen Bio Holdings Inc. has entered into a securities purchase agreement, raising $6 million through the sale of Series C Preferred Stock to an existing investor.

Tevogen Bio Holdings Inc. repurchased all outstanding Series B Preferred Stock and received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement.

Tevogen Bio Holdings Inc. has entered into a loan agreement for a $36 million credit facility and a contingent option for a $14 million private equity placement.

Tevogen Bio Holdings Inc. files an amendment to its Form 8-K to correct a reference to private company auditing standards and includes audited financial statements for 2022 and 2023.

Tevogen Bio Holdings Inc. has entered into a term sheet for a $36 million credit facility and a contingent option for a $14 million private equity placement with The Patel Family, LLP.

Tevogen Bio Holdings Inc. has appointed KPMG as its new independent registered public accounting firm, replacing Marcum LLP, effective April 29, 2024.

Tevogen Bio Holdings Inc. has filed an amendment to its previous report to include the audited financial statements of Tevogen Bio Inc. for the years ended December 31, 2023 and 2022, along with pro forma financial information following its recent merger.

Tevogen Bio reports the elimination of $94.9 million in liabilities through the conversion of promissory notes to common stock, alongside the launch of an AI initiative and new leadership appointments.

Tevogen Bio Holdings Inc. amended a securities purchase agreement, securing $6 million through the sale of Series A-1 Preferred Stock.

Tevogen Bio Holdings Inc. has entered into an amended agreement to sell Series A-1 Preferred Stock for $6 million, enhancing its financial position.

Tevogen Bio Holdings Inc. has filed certificates of designation for Series A and B preferred stock, securing an $8 million investment and addressing prior liabilities.

Tevogen Bio Holdings Inc. has adopted a new Code of Business Conduct and Ethics, effective February 14, 2024, to ensure ethical and legal standards across the company.

Tevogen Bio Holdings finalized a business combination, secured an $8 million investment through a Series A Preferred Stock offering, and restructured over $4.2 million in liabilities.

Tevogen Bio Inc. has entered into a $10 million convertible promissory note agreement and subsequently amended it to facilitate a potential SPAC transaction and extend the maturity date.